ArticleBone2026
Osteoporosis treatment adherence trajectories, comedication patterns, and romosozumab persistence among early users: A data-driven analysis.
Article in Bone, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo evaluate whether previous osteoporosis treatment adherence trajectories and comedication patterns at romosozumab initiation are associated with romosozumab treatment persistence among Medicare beneficiaries initiating romosozumab in the early post-approval period.
methodsWe used Medicare data (2016-2022) to identify women aged ≥65 initiating romosozumab in 2019. Prior osteoporosis treatment over the 36-month baseline was summarized as monthly proportion of days covered and grouped into adherence trajectories using group-based trajectory modeling (GBTM). Comedication patterns on the romosozumab initiation day were derived from eight drug categories using consensus clustering. Primary outcome was early romosozumab persistence, assessed in three successive 60-day windows (30-day dosing interval plus 30-day permissible gap) after the first, second, and third doses, defined as receipt of the subsequent dose. Secondary analysis assessed romosozumab discontinuation. Models adjusted for covariables selected via LASSO approach.
resultsAmong 1746 early romosozumab users, 70.8% had prior osteoporosis therapy, with four adherence trajectories identified by GBTM. Compared with consistently high prior adherence, no prior therapy was associated with lower treatment persistence (adjusted HR[aHR] = 0.91, 95% CI[0.85, 0.97], p = 0.003), while declining prior adherence was associated with increased risk of romosozumab discontinuation before completion (aHR = 1.35[1.09, 1.68], p = 0.007). Consensus clustering analysis identified five comedication patterns. Patterns characterized by antidepressants and/or antihypertensives were associated with increased risk of discontinuation compared with those using none of the eight drug categories at romosozumab initiation.
conclusionsData-driven stratification based on prior treatment behavior and comedications identifies romosozumab early users at higher risk of non-persistence and may inform individualized support to maintain treatment persistence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.